{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:03:27Z","timestamp":1793833407549,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Science, Sports and Culture, Japan","doi-asserted-by":"crossref","award":["16H05175"],"award-info":[{"award-number":["16H05175"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Science, Sports and Culture, Japan","doi-asserted-by":"crossref","award":["25860270"],"award-info":[{"award-number":["25860270"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We previously reported the identification of monocarboxylate transporter 4 (MCT4) and glypican-3 (GPC3) as prognostic factors for hepatocellular carcinoma (HCC), which are now considered significant poor prognostic factors for the disease. This study aimed to clarify the detailed interaction of these two factors in HCC to improve our understanding of aggressive HCC phenotypes. A total of 225 Japanese patients with HCC from our previous study were subjected to immunohistochemical analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of MCT4-positive (MCT4+) HCC cases was 47 (21%), and most MCT4+ HCC showed high GPC3 expression (94%, 44\/47 cases). In 44 MCT4+\/GPC3+ HCC cases, intratumoral heterogeneity of GPC3 or MCT4 expression was further evaluated. We observed reciprocal (inverse), synergistic, mixed reciprocal and synergistic, or irrelevant interaction of MCT4 and GPC3 expression in 29 (66%), 5 (11%), 1 (2%), and 9 cases (21%), respectively. The cases exhibiting reciprocal expression of both markers tended to have cirrhosis without a history of neoadjuvant therapy. In summary, although MCT4+ HCC cases are mostly GPC3+, intratumoral expression patterns of MCT4 and GPC3 are frequently reciprocal each other, suggesting that dual targeting of MCT4 and GPC3 may achieve a better antitumor effect for MCT4+ HCC cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-019-4778-y","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T11:03:00Z","timestamp":1573297380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas"],"prefix":"10.1186","volume":"12","author":[{"given":"Kenji","family":"Yorita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ohtomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-0451","authenticated-orcid":false,"given":"Hiroaki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"key":"4778_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lort-Tetieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"4778_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1478-3231.2010.02359.x","volume":"31","author":"K Yorita","year":"2011","unstructured":"Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int. 2011;31:120\u201331.","journal-title":"Liver Int."},{"key":"4778_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/ijc.29518","volume":"137","author":"Y Haruyama","year":"2015","unstructured":"Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, et al. High pre-operative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137:1643\u201351.","journal-title":"Int J Cancer"},{"key":"4778_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/liv.12466","volume":"34","author":"A Ohno","year":"2014","unstructured":"Ohno A, Yorita K, Haruyama Y, Kondo K, Kato A, Ohtomo T, et al. Aberrant expression of monocarboxylate transporter 4 in tumor cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int. 2014;34:942\u201352.","journal-title":"Liver Int."},{"key":"4778_CR5","first-page":"546","volume":"59","author":"J Filmus","year":"1999","unstructured":"Filmus J, Song H, Shi W, Duenas Gonzalez A, Kaya M, Cano-Gauci D. Glypican-3 is a novel inhibitor of insulin-like growth factor signaling. Medicina (B Aires). 1999;59:546.","journal-title":"Medicina (B Aires)."},{"key":"4778_CR6","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245\u201354.","journal-title":"Cancer Res"},{"key":"4778_CR7","doi-asserted-by":"publisher","first-page":"e11130","DOI":"10.1097\/MD.0000000000011130","volume":"97","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang M, Ma H, Song X, He L, Ye X, et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: an updated meta-analysis. Medicine (Baltimore). 2018;97:e11130.","journal-title":"Medicine (Baltimore)."},{"key":"4778_CR8","doi-asserted-by":"publisher","first-page":"e9702","DOI":"10.1097\/MD.0000000000009702","volume":"97","author":"H Liu","year":"2018","unstructured":"Liu H, Yang C, Lu W, Zeng Y. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97:e9702.","journal-title":"Medicine (Baltimore)."},{"key":"4778_CR9","doi-asserted-by":"publisher","first-page":"242437","DOI":"10.1155\/2015\/242437","volume":"2015","author":"CD Bovenzi","year":"2015","unstructured":"Bovenzi CD, Hamilton J, Tassone P, Johnson J, Cognetti DM, Luginbuhl A, et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta-analysis. Biomed Res Int. 2015;2015:242437.","journal-title":"Biomed Res Int"},{"key":"4778_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10863-012-9428-1","volume":"44","author":"C Pinheiro","year":"2012","unstructured":"Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012;44:127\u201339.","journal-title":"J Bioenerg Biomembr"},{"key":"4778_CR11","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1074\/jbc.M511397200","volume":"281","author":"MS Ullah","year":"2006","unstructured":"Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006;281:9030\u20137.","journal-title":"J Biol Chem"},{"key":"4778_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/mol.116.107706","volume":"92","author":"XX Xiong","year":"2017","unstructured":"Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Mol Pharmacol. 2017;92:246\u201355.","journal-title":"Mol Pharmacol"},{"key":"4778_CR13","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896\u2013904.","journal-title":"EMBO J"},{"key":"4778_CR14","first-page":"3154","volume":"53","author":"H Kataoka","year":"1993","unstructured":"Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res. 1993;53:3154\u20138.","journal-title":"Cancer Res"},{"key":"4778_CR15","first-page":"434","volume":"55","author":"C Biswas","year":"1995","unstructured":"Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434\u20139.","journal-title":"Cancer Res"},{"key":"4778_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00432-014-1888-8","volume":"141","author":"HJ Gao","year":"2015","unstructured":"Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, et al. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol. 2015;141:1151\u201362.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4778_CR17","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1002\/cam4.1521","volume":"7","author":"HL Chen","year":"2018","unstructured":"Chen HL, OuYang HY, Le Y, Jiang P, Tang H, Yu ZS, et al. Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. Cancer Med. 2018;7:5339\u201350.","journal-title":"Cancer Med"},{"key":"4778_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.acthis.2008.11.025","volume":"112","author":"H Takai","year":"2010","unstructured":"Takai H, Kato A, Ishiguro T, Kinoshita Y, Karasawa Y, Otani Y, et al. Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochem. 2010;112:240\u201350.","journal-title":"Acta Histochem"},{"key":"4778_CR19","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","volume":"68","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832\u20138.","journal-title":"Cancer Res"},{"key":"4778_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","volume":"378","author":"K Nakano","year":"2009","unstructured":"Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009;378:279\u201384.","journal-title":"Biochem Biophys Res Commun"},{"key":"4778_CR21","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1038\/sj.onc.1204925","volume":"20","author":"YY Xiang","year":"2001","unstructured":"Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene. 2001;20:7408\u201312.","journal-title":"Oncogene"},{"key":"4778_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.onc.1203322","volume":"19","author":"SS Murthy","year":"2000","unstructured":"Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 2000;19:410\u20136.","journal-title":"Oncogene"},{"key":"4778_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature19081","volume":"537","author":"B Thienpont","year":"2016","unstructured":"Thienpont B, Steinbacher J, Zhao H, D\u2019Anna F, Kuchnio A, Ploumakis A, et al. Tumor hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016;537:63\u20138.","journal-title":"Nature"},{"key":"4778_CR24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/hep.21825","volume":"46","author":"LA Morford","year":"2007","unstructured":"Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology. 2007;46:1541\u20137.","journal-title":"Hepatology"},{"key":"4778_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.biocel.2014.08.021","volume":"55","author":"F Luan","year":"2014","unstructured":"Luan F, Liu P, Ma H, Yue X, Liu J, Gao L, et al. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. Int J Biochem Cell Biol. 2014;55:129\u201335.","journal-title":"Int J Biochem Cell Biol"},{"key":"4778_CR26","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.bbrc.2008.03.027","volume":"369","author":"A Taguchi","year":"2008","unstructured":"Taguchi A, Emoto M, Okuya S, Fukuda N, Nakamori Y, Miyazaki M, et al. Identification of Glypican3 as a novel GLUT4-binding protein. Biochem Biophys Res Commun. 2008;369:1204\u20138.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4778-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T19:34:23Z","timestamp":1604777663000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4778"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4778-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.15684\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15684\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1975, as revised in 1983, and approved by the Institutional Review Board of the Faculty of Medicine, University of Miyazaki. Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HK receives collaborative research funding from Chugai Pharmaceutical Co. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"741"}}